Literature DB >> 29474262

Longitudinal Changes in Body Composition by Dual-energy Radiograph Absorptiometry Among Perinatally HIV-infected and HIV-uninfected Youth: Increased Risk of Adiposity Among HIV-infected Female Youth.

Tanvi S Sharma1, Gabriel Somarriba2, Kristopher L Arheart3, Daniela Neri4, M Sunil Mathew5, Patricia L Graham5, Gwendolyn B Scott6, Tracie L Miller5.   

Abstract

BACKGROUND: Combination antiretroviral therapy has allowed youth with perinatal HIV infection (PHIV+) to live into adulthood, but many youth may experience metabolic and body composition changes that predispose to greater cardiovascular disease (CVD) risk. This longitudinal study evaluated changes in body composition measured by dual-energy radiograph absorptiometry (DXA) in a cohort of PHIV+ youth compared with HIV- controls over a 7-year period.
METHODS: PHIV+ youth and HIV- controls were prospectively enrolled in a single-site study to assess nutrition and CVD risk. Anthropometrics and DXA scans were longitudinally obtained to assess percent body fat and regional fat distribution. Using general linear models, we analyzed differences in body composition and anthropometric measures by sex between PHIV+ youth and controls over time.
RESULTS: Two hundred thirty-five participants (156 PHIV+ and 79 HIV- controls) with at least 1 DXA performed since study enrollment were included for analysis. During the study period, 471 DXAs were obtained in the PHIV+ group and 95 in HIV- controls. PHIV+ females demonstrated greater increase in weight and body mass index over time compared with HIV- females, and significant increases in total percent body fat [estimate = 1.212 (95% confidence interval: 0.837-1.587) percent per year; P < 0.001) and percent trunk fat [1.3818 (95% confidence interval: 0.922-1.84); P < 0.001] compared with HIV- females and PHIV+ males.
CONCLUSIONS: PHIV+ females demonstrate an unfavorable change in fat redistribution and percent body fat over time that exceeds the pattern seen in PHIV+ males or HIV- females. Providers should have heightened awareness of body composition changes of PHIV+ females that may eventually lead to increased CVD risk.

Entities:  

Mesh:

Year:  2018        PMID: 29474262      PMCID: PMC6105572          DOI: 10.1097/INF.0000000000001963

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  35 in total

1.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

2.  Relation of body fat patterning to lipid and lipoprotein concentrations in children and adolescents: the Bogalusa Heart Study.

Authors:  D S Freedman; S R Srinivasan; D W Harsha; L S Webber; G S Berenson
Journal:  Am J Clin Nutr       Date:  1989-11       Impact factor: 7.045

3.  Food insecurity and obesogenic maternal infant feeding styles and practices in low-income families.

Authors:  Rachel S Gross; Alan L Mendelsohn; Arthur H Fierman; Andrew D Racine; Mary Jo Messito
Journal:  Pediatrics       Date:  2012-07-23       Impact factor: 7.124

4.  Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus.

Authors:  Siobán D Harlow; Mardge Cohen; Suzanne E Ohmit; Paula Schuman; Susan Cu-Uvin; Xihong Lin; Ruth Greenblatt; Alejandra Gurtman; Ann Khalsa; Howard Minkoff; Mary A Young; Robert S Klein
Journal:  Am J Obstet Gynecol       Date:  2003-04       Impact factor: 8.661

5.  Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women.

Authors:  Kathleen V Fitch; Suman Srinivasa; Suhny Abbara; Tricia H Burdo; Kenneth C Williams; Peace Eneh; Janet Lo; Steven K Grinspoon
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

6.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

7.  Changes in macronutrient intake among HIV-infected children between 1995 and 2004.

Authors:  Tanvi S Sharma; Daniel D Kinnamon; Christopher Duggan; Geoffrey A Weinberg; Lauren Furuta; Lori Bechard; Jeanne Nicchitta; Sherwood L Gorbach; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

8.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

9.  Do stress reactions cause abdominal obesity and comorbidities?

Authors:  P Björntorp
Journal:  Obes Rev       Date:  2001-05       Impact factor: 9.213

10.  HIV infection and cardiovascular disease in women.

Authors:  Julie A Womack; Chung-Chou H Chang; Kaku A So-Armah; Charles Alcorn; Jason V Baker; Sheldon T Brown; Matthew Budoff; Adeel A Butt; Cynthia Gibert; Matthew Bidwell Goetz; John Gottdiener; Stephen Gottlieb; Amy C Justice; David Leaf; Kathleen McGinnis; David Rimland; Maria C Rodriguez-Barradas; Jason Sico; Melissa Skanderson; Hilary Tindle; Russell P Tracy; Alberta Warner; Matthew S Freiberg
Journal:  J Am Heart Assoc       Date:  2014-10-16       Impact factor: 5.501

View more
  7 in total

1.  Sex differences in neurocognitive screening among adults living with HIV in China.

Authors:  Xiaotong Qiao; Haijiang Lin; Xiaoxiao Chen; Chenxi Ning; Keran Wang; Weiwei Shen; Xiaohui Xu; Xiaoyi Xu; Xing Liu; Na He; Yingying Ding
Journal:  J Neurovirol       Date:  2019-02-13       Impact factor: 2.643

2.  Gut Dysfunction Markers Are Associated With Body Composition in Youth Living With Perinatally Acquired Human Immunodeficiency Virus.

Authors:  Sahera Dirajlal-Fargo; Denise L Jacobson; Wendy Yu; Ayesha Mirza; Mitchell E Geffner; Jennifer Jao; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2022-09-29       Impact factor: 20.999

Review 3.  Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy.

Authors:  Sahera Dirajlal-Fargo; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2021-10-15       Impact factor: 5.495

4.  Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV.

Authors:  Junwei Su; Stephanie Shiau; Stephen M Arpadi; Renate Strehlau; Megan Burke; Faeezah Patel; Louise Kuhn; Ashraf Coovadia; Michael T Yin
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-01-01       Impact factor: 2.839

5.  Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment.

Authors:  Linda Aurpibul; Sirianong Namwongprom; Tavitiya Sudjaritruk; Sakaewan Ounjaijean
Journal:  PLoS One       Date:  2020-03-30       Impact factor: 3.240

6.  Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents.

Authors:  Neil Thivalapill; Tandzile Simelane; Nobuhle Mthethwa; Sandile Dlamini; Bhekumusa Lukhele; Velephi Okello; H Lester Kirchner; Anna M Mandalakas; Alexander W Kay
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

7.  Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort.

Authors:  Wei Li A Koay; Sahera Dirajlal-Fargo; Matthew E Levy; Paige Kulie; Anne Monroe; Amanda D Castel; Natella Y Rakhmanina
Journal:  Open Forum Infect Dis       Date:  2021-07-01       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.